Genmab A/S (GMAB) Reports 75%/67% ORR in Phase 2 mCRC

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

Genmab reported Phase 2 trial results for petosemtamab in mCRC, showing 75% ORR in first-line and 67% in second-line patients. The data support ongoing global Phase 3 trials, according to the company.

Genmab and Incyte will collaborate on a Phase 1/2 trial combining Genmab's petosemtamab with Incyte's INCB161734 and chemotherapy for first-line colorectal cancer with KRAS G12D mutation. Genmab will lead the study, with Incyte co-funding and supplying its drug. Both companies' shares closed at $43.79 and $115.71 respectively before the announcement.

Genmab (GMAB) and Incyte (INCY) will collaborate on a Phase 1/2 trial for a combination therapy targeting KRAS G12D-mutated metastatic colorectal cancer. Genmab's petosemtamab and Incyte's INCB161734 will be tested with standard chemotherapy. Incyte will supply the drug and co-fund the trial, while Genmab leads the study.

Genmab and Incyte are collaborating on clinical trials for metastatic colorectal cancer. The trials will evaluate the combination of Genmab's petosemtamab and Incyte's INCB161734 with standard chemotherapy. Petosemtamab targets EGFR and LGR5, while INCB161734 inhibits KRAS G12D. The companies aim to provide a new treatment option for patients with KRAS G12D-mutated metastatic colorectal cancer.

Genmab and Incyte will collaborate on a Phase 1/2 trial of petosemtamab with Incyte's KRAS G12D inhibitor and chemotherapy for metastatic colorectal cancer. Incyte will co-fund and supply its drug. The study targets a high-need population, with potential for further development if successful.